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incidence
The crude incidence of ovarian cancer in the European Union
is 18, the mortality is 12/100 000 women/year. The median
age at diagnosis is 63 years. The incidence increases with age
and peaks in the eighth decade.
diagnosis
The definitive diagnosis of epithelial ovarian cancer requires
a surgical specimen. Pathological diagnosis should be made
according to the WHO classification. Established subtypes are:
serous, mucinous, endometrioid, clear cell, transitional cell,
mixed and undifferentiated carcinomas.
staging and risk assessment
Surgical staging requires a median laparotomy with a thorough
examination of the abdominal cavity according to Fe´de´ration
Internationale de Gyne´cologie et d’Obste´trique (FIGO)
classification guidelines. If disease appears confined to the
ovary, biopsy of the diaphragmatic peritoneum, paracolic
gutters, pelvic peritoneum, an infracolic omentectomy and
sampling or dissection of para-aortic and pelvic nodes are
required in addition to peritoneal washings.
Surgery should be performed by an appropriately trained
gynaecologic oncologist with experience in the management of
ovarian cancer [III, B].
Staging is described using the FIGO and American Joint
Committee on Cancer (AJCC) classification as in Table I.
Established favorable prognostic factors besides surgical stage
are: small tumor volume (before and after surgery), younger
age, good performance status, cell type other than mucinous or
clear cell, well-differentiated tumor and absence of ascites. Low
grade, absence of dense adhesions, minimal ascites, subgroups
a/b versus c and cell type other than clear cell are considered
good prognostic factors for patients with stage I disease.
Before surgery and/or chemotherapy, patients should have
a CT scan of the abdomen and pelvis, chest X-ray, serum
CA125, complete blood count and differential, and
biochemistry for renal and hepatic function. The routine use of
FDG-PET–CT for initial staging is not recommended.
treatment plan
The selection of the type of surgery and postoperative
chemotherapy depends upon the stage and other
clinicopathological prognostic factors.
early stage disease, FIGO stage I and IIa
Surgery should involve total abdominal hysterectomy, bilateral
salpingo-oophorectomy, omentectomy, random peritoneal
biopsies including the paracolic gutters and at least pelvic/para-
aortic lymph node sampling performed as described above. In
younger patients with localized, unilateral tumors (stage I) and
favorable histology, who wish to conserve fertility, unilateral
salpingo-oophorectomy may not be associated with a high risk
of recurrence. Wedge biopsy of the contralateral ovary should
be performed, if the contralateral ovary is not normal on
inspection. FIGO stage I tumors with dense adhesions to other
pelvic structures should be ‘upstaged’ and treated as FIGO II
tumors, as the relapse rate appears to be similar [IV].
FIGO stage Ia/b, well-differentiated, non-clear cell histology:
surgery alone is adequate [I, A]. FIGO stage Ia/b poorly
differentiated, densely adherent, clear cell histology and all
grades FIGO stage Ic and IIA: optimal surgery and staging
should be performed, and adjuvant chemotherapy considered
[I, A].
Consider three cycles of carboplatin AUC 5–7 mg/ml/min +
paclitaxel 175 mg/m2/3 h for non-serous early stage ovarian
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cancer if combination therapy is to be used [II, B]. Otherwise,
six cycles of carboplatin 6 paclitaxel would seem appropriate.
advanced disease, FIGO stage IIb–IIIc
Surgery should include total abdominal hysterectomy and
bilateral salpingo-oophorectomy with omentectomy, with
staging biopsies performed as described. Up-front maximal
surgical effort at cytoreduction with the goal of no residual
disease should be undertaken.
The recommended standard chemotherapy for advanced
ovarian carcinoma, stages IIb–IIIc is carboplatin AUC 5–7 mg/
ml/min6 paclitaxel 175 mg/m2/3 h every 3 weeks for six cycles.
Patients should receive optimal doses of chemotherapy based
on measured glomerular filtration rate (GFR) and actual body
weight; dose reductions for obesity are discouraged [III].
If initial maximal cytoreduction was not performed, interval
debulking surgery should be considered in patients responding
to chemotherapy, or showing stable disease [II, B]. Interval
debulking surgery should ideally be performed after three cycles
of chemotherapy, followed by three further cycles of
chemotherapy.
There is no evidence of a survival benefit for ‘second-look’
surgery following completion of chemotherapy in patients
whose disease appears to be in complete remission. Such
procedures should only be undertaken as part of a clinical trial.
Likewise, the value of secondary tumor reduction at the time of
second-look laparotomy is not clear.
Intraperitoneal chemotherapy should be considered an
option in centers where the expertise exists.
Neoadjuvant chemotherapy for patients considered initially
not optimally resectable for either tumor or patient-related
factors is a viable alternative strategy; however, available data
suggest that the survival outcome may be inferior to that from
successful primary surgery followed by chemotherapy.
advanced disease, FIGO stage IV
Patients with stage IV disease may obtain a survival advantage
from being maximally surgically cytoreduced at initial
laparotomy [III, B], although randomized trials have not
addressed this question.
Younger patients with good performance status, pleural
effusion as the only site of disease outside the abdominal cavity,
small volume metastases and no major organ dysfunction
should be considered for surgery as outlined for FIGO stage
IIb–III disease.
If surgery is not planned, the diagnosis should be confirmed
by biopsy and chemotherapy administered as recommended
above for FIGO stage IIb–IIIc disease.
response evaluation
CA125 levels during chemotherapy correlate with tumor
response and with survival [III, A]. Serum CA125 should be
measured at regular intervals during chemotherapy (e.g. before
each cycle).
For patients with abnormal CT scan at baseline, this should
be repeated after cycle 6 unless there is evidence (e.g. CA125
levels not falling) of non-responding disease; in this case an
earlier CT scan would be indicated. Patients with normal CT
scans at baseline do not need further CT scans, provided there
is no clinical or biochemical indication of disease progression.
An interim CT scan after three cycles of chemotherapy should
be considered for a patient who is negative for serum CA125, or
for whom interval debulking surgery is being considered.
Current data do not support a recommendation of
maintenance/consolidation treatment beyond six cycles;
however, the data for 12 months of paclitaxel maintenance may
be discussed with patients with respect to the potential
improvement observed in PFS [II, C], especially in patients
with low concentrations of CA125 [III, B]. Patients with
a partial response (or elevated CA125) after six cycles of
chemotherapy but continuing evidence of response by CA125
can be considered for a further three cycles of the same
chemotherapy [V, D].
follow-up
History, physical examination including pelvic examination
every 3 months for 2 years, every 4 months during the third
year and every 6 months during years 4 and 5 or until
progression is documented.
CA125 can accurately predict tumor relapse [I, A], and may
be performed at follow-up visits. It is unknown, however,
whether the early detection of recurrence by CA125 offers any
advantage. CT scans should be performed if there is clinical or
CA125 evidence of progressive disease. FDG-PET–CT scans
may be superior to CT scans in detecting small volume
operable relapses [III, B].
recurrent disease
Patients with long intervals (>1 year) from primary surgery
should be considered for surgical resection of recurrent disease
[III, A]. Patients with long intervals (>6 months) from initial
Table 1. Staging using the Fe´de´ration Internationale de Gyne´cologie et
d’Obste´trique (FIGO) and American Joint Committee on Cancer (AJCC)
classification
Stage I Limited to ovaries
Ia One ovary
Ib Both ovaries
Ic Ruptured capsule, surface tumor
or positive washingsa
Stage II Pelvic extension
IIa Uterus, tube(s)
IIb Other pelvic tissue
IIc Positive washings, ascites
Stage III Abdominal extension and/or regional lymph nodes
IIIa Microscopic peritoneal metastases
IIIb Macroscopic peritoneal metastases £2 cm
IIIc Macroscopic peritoneal metastases >2 cm and/or
regional lymph nodes
Stage IV Distant metastases outside peritoneal cavity
aFor the estimation of the prognosis, this includes iatrogenic intraoperative
rupture
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chemotherapy should be offered platinum-based combination
chemotherapy (carboplatin + paclitaxel, carboplatin +
gemcitabine) [I, A]. For patients with short treatment-free
intervals and with second and later recurrences, palliative
chemotherapy with pegylated liposomal doxorubicin,
gemcitabine or topotecan should be considered [II, B].
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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